Metformin in the treatment of HIV lipodystrophy syndrome - A randomized controlled trial

被引:262
作者
Hadigan, C
Corcoran, C
Basgoz, N
Davis, B
Sax, P
Grinspoon, S
机构
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Combined Program Pediat Gastroenterol & Nutr, Boston, MA USA
[4] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Infect Dis, Boston, MA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 284卷 / 04期
关键词
D O I
10.1001/jama.284.4.472
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context A syndrome of lipodystrophy, characterized by fat redistribution and insulin resistance, has been estimated to affect the majority of human immunodeficiency virus (HIV)-infected individuals who are treated with combination antiretroviral therapy. There are no proven therapies for the metabolic disturbances associated with HIV lipodystrophy syndrome. Objective To determine the safety and efficacy of metformin therapy in HIV-infected patients with fat redistribution and abnormal glucose homeostasis. Design and Setting Randomized, double-blind, placebo-controlled pilot study conducted in a university hospital between December 1998 and January 2000, Patients Twenty-six HIV-infected, nondiabetic patients with fat redistribution and abnormal oral glucose tolerance test (OGTT) results, hyperinsulinemia, or both. Interventions Patients were randomly assigned to receive metformin, 500 mg twice daily (n=14), or identical placebo (n=12), for 3 months. Main Outcome Measures Insulin area under the curve (AUC), calculated 120 minutes following a 75-g OGTT at baseline vs at 3-month follow-up and compared between treatment groups. Results Patients treated with metformin demonstrated significant reductions in mean (SEM) insulin AUC 120 minutes after OGTT (-2930 [912] vs -414 [432] mu IU/mL [-20349 (6334) vs -2875 {3000} pmol/L]; P=.01), weight (-1.3 [0.6] vs 1.1[0.4] kg; P=.005), and diastolic blood pressure (-5 [4] vs 5 [2] mm Hg; P=.009) vs controls, respectively. Metformin therapy was associated with a decrease in visceral abdominal fat (VAT; -1115 [819] vs 1191 [699] mm(2); P=.08) and a proportional reduction in subcutaneous abdominal fat (SAT); the VAT-SAT ratio was unchanged in metformin-treated vs placebo-treated patients. No increase in lactate or liver transaminase levels was observed with metformin treatment. Mild diarrhea was the most common adverse effect of metformin. No patient discontinued therapy because of adverse effects. Conclusions This study suggests that a relatively low dosage of metformin reduces insulin resistance and related cardiovascular risk parameters in HIV-infected patients with lipodystrophy.
引用
收藏
页码:472 / 477
页数:6
相关论文
共 26 条
[1]   EXPLORATION OF SIMPLE INSULIN SENSITIVITY MEASURES DERIVED FROM FREQUENTLY SAMPLED INTRAVENOUS GLUCOSE-TOLERANCE (FSIGT) TESTS - THE INSULIN-RESISTANCE ATHEROSCLEROSIS STUDY [J].
ANDERSON, RL ;
HAMMAN, RF ;
SAVAGE, PJ ;
SAAD, MF ;
LAWS, A ;
KADES, WW ;
SANDS, RE ;
CEFALU, W .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1995, 142 (07) :724-732
[2]   ASSESSMENT OF ABDOMINAL FAT-CONTENT BY COMPUTED-TOMOGRAPHY [J].
BORKAN, GA ;
GERZOF, SG ;
ROBBINS, AH ;
HULTS, DE ;
SILBERT, CK ;
SILBERT, JE .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1982, 36 (01) :172-177
[3]   Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy [J].
Brinkman, K ;
Smeitink, JA ;
Romijn, JA ;
Reiss, P .
LANCET, 1999, 354 (9184) :1112-1115
[4]   Body-mass index and mortality in a prospective cohort of US adults [J].
Calle, EE ;
Thun, MJ ;
Petrelli, JM ;
Rodriguez, C ;
Heath, CW .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (15) :1097-1105
[5]   Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study [J].
Carr, A ;
Samaras, K ;
Thorisdottir, A ;
Kaufmann, GR ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1999, 353 (9170) :2093-2099
[6]   Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance [J].
Carr, A ;
Samaras, K ;
Chisholm, DJ ;
Cooper, DA .
LANCET, 1998, 351 (9119) :1881-1883
[7]   An audit of place of death of cancer patients in a semi-rural Scottish practice [J].
Carroll, DS .
PALLIATIVE MEDICINE, 1998, 12 (01) :51-53
[8]   Pharmacologic therapy for type 2 diabetes mellitus [J].
DeFronzo, RA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) :281-303
[9]   Hyperinsulinemia as an independent risk factor for ischemic heart disease [J].
Despres, JP ;
Lamarche, B ;
Mauriege, P ;
Cantin, B ;
Dagenais, GR ;
Moorjani, S ;
Lupien, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (15) :952-957
[10]  
Dong KL, 1999, J ACQ IMMUN DEF SYND, V21, P107